IL-27R?: A Novel Molecular Imaging Marker for Allograft Rejection.
Ontology highlight
ABSTRACT: Non-invasively monitoring allogeneic graft rejection with a specific marker is of great importance for prognosis of patients. Recently, data revealed that IL-27R? was up-regulated in alloreactive CD4+ T cells and participated in inflammatory diseases. Here, we evaluated whether IL-27R? could be used in monitoring allogeneic graft rejection both in vitro and in vivo. Allogeneic (C57BL/6 donor to BALB/c recipient) and syngeneic (BALB/c both as donor and recipient) skin grafted mouse models were established. The expression of IL-27R? in grafts was detected. The radio-probe, 125I-anti-IL-27R? mAb, was prepared. Dynamic whole-body phosphor-autoradiography, ex vivo biodistribution and immunofluorescence staining were performed. The results showed that the highest expression of IL-27R? was detected in allogeneic grafts on day 10 post transplantation (top period of allorejection). 125I-anti-IL-27R? mAb was successfully prepared with higher specificity and affinity. Whole-body phosphor-autoradiography showed higher radioactivity accumulation in allogeneic grafts than syngeneic grafts on day 10. The uptake of 125I-anti-IL-27R? mAb in allogeneic grafts could be almost totally blocked by pre-injection with excess unlabeled anti-IL-27R? mAb. Interestingly, we found that 125I-anti-IL-27R? mAb accumulated in allogeneic grafts, along with weaker inflammation earlier on day 6. The high uptake of 125I-anti-IL-27R? mAb was correlated with the higher infiltrated IL-27R? positive cells (CD3+/CD68+) in allogeneic grafts. In conclusion, IL-27R? may be a novel molecular imaging marker to predict allorejection.
SUBMITTER: Zhao S
PROVIDER: S-EPMC7072931 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA